The development and introduction of several sorts of technologies by manufacturers for the production of cell therapies is anticipated to fuel the market's expansion. For instance, the debut of new korus technology for the creation of autologous cell treatment was announced by INVETECH, a global firm that provides solutions, systems, and services for cell and gene therapy, in July 2022. A closed system for the manufacture of autologous cell therapy is called Korus. Using mild counterflow centrifugation to provide elutriation and cell washing in order to eliminate impurities and produce a pure population of target cells. The regulatory approvals that manufacturers of cell therapy products are obtaining to improve their cell therapy manufacturing processes are anticipated to fuel the expansion of the worldwide cell therapy manufacturing market. For instance, the U.S. Food and Drug Administration announced in May 2022 that it had authorised Novartis' Kymriah, a chimeric antigen receptor (CAR) T-cell therapy, for the treatment of people with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Coherent Market Insights projects that the global Cell Therapy Manufacturing Market will reach US$ 3,755.4 million in 2022 and grow at a CAGR of 15.2% during the following five years (2022-2030).
Major Players in the Cell Therapy Manufacturing Industry:
1. Wuxi AppTec, Inc
The company was established in 2000 and has its head office in Shanghai, China. The business manufactures biological agents, antibodies, diagnostic tools, and other products. Other services offered by WuXi AppTec include technological research and biological analysis. WuXi AppTec planned to construct a new site in Singapore in June 2022 in order to better serve its international partners and advance healthcare innovation. WuXi AppTec announced in February 2023 that company has won the "Industry Mover" prize in the S&P Global Sustainability Yearbook 2023.
2. Lineage Cell Therapeutics, Inc.
The business was established in 1990 and is based in Carlsbad, California, United States. The business is a biotechnology firm that provides gene-marker-based molecular diagnostics and cell-based therapeutics for illnesses and degenerative ailments. Lineage declared in December 2021 that Genentech, a part of the Roche Group, had agreed to an exclusive $670 million global agreement for the creation and marketing of OpRegen.
3. HEALIOS K.K.,
The company was founded in 2011 and has its headquarters in Japan. Healios K.K. conducts research and creates compound drugs and iPSC regenerative medicine. The business conducts research to create a therapy for age-related macular degeneration. Healios KK is involved in the study, creation, and marketing of cellular and regenerative medicine.
4. Lonza,
The business was established in 1897 and is located in Basel, Switzerland. The company offers custom-made biopharmaceutical manufacturing, as well as detection systems and services for the bioscience industry, in addition to product development services to the pharmaceutical and biologic industries. Lonza Specialty Ingredients sold itself to Bain and Cinven for CHF 4.2 billion in July 2021. Lonza declared in February 2023 that the expansion of their bioconjugation facility in Visp (CH) was finished as planned.
5. Merck KGaA
The company has its headquarters in Darmstadt, Germany, and was established in 1668. The corporation is split into the life sciences, electronics, and healthcare sectors. The sale of Merck's Allergopharma subsidiary to Dermapharm for an unknown sum was announced in February 2020. In December 2021, the US and Canadian subsidiaries of the Merck Group, EMD Serono, announced that it will acquire Chord Therapeutics, a Swiss company, along with its flagship drug, cladribine.
6. Takara Bio Inc.
The business was established in 2002 and is based in Kusatsu, Shiga, Japan. The business conducts research and produces reagents for genome engineering and analysis, technology for gene therapy, and natural health food items containing extracts and bodies of seaweed and mushrooms. Takara Bio unveiled "CereAAVTM," a novel brain-tropic AAV vector, for gene therapy in April 2022.
7. Astellas Pharma Inc.
The business was established in 2005 and is headquartered in Chuo City, Tokyo, Japan. The business is involved in pharmaceutical product research, development, manufacturing, import, and export. Astellas declared in October 2020 that it will pay $127.5 million to purchase iota Biosciences, Inc. The business stated in August 2022 that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for fezolinetant.
*Definition: Human cells are transplanted in cellular therapy to replace or repair tissue or cells that have been destroyed. With the use of cutting edge technologies, innovative products, and limitless imagination, a variety of distinct cell types may be utilised as part of a therapy or treatment for a range of diseases and disorders.
